Inhibikase Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accounting Fees and Services
The following table sets forth the aggregate fees billed by CohnReznick LLP in connection with audit and other services rendered during the past two fiscal years.
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Audit Fees (1) | $259,927 | $238,900 |
| Audit-Related Fees (2) | — | 40,145 |
| Tax Fees (3) | 42,685 | 23,000 |
| $302,612 | $302,045 | |
(1)
Audit fees in 2023 and 2022 include fees related to the annual audit of the Company’s financial statements, the review of the interim financial statements included in our quarterly reports on Form 10-Q, and comfort letters, consents and assistance with and review of documents filed with the SEC.
(2)
Audit related fees represent fees for professional services rendered during 2022 in connection with our 2019 NIH grants program (“Yellow Book”) audit. Audit related fees represent fees for professional services rendered during 2022 in connection with our 2021 and 2020 Yellow Book audits.
(3)
Tax fees are related to tax compliance, tax advice and tax planning services, including the review and preparation of our federal and state income tax returns.
The Audit Committee pre-approved all services described above in accordance with the pre-approval policies and procedures described below.
INDEX TO FINANCIAL STATEMENTS
| Page | | |
| Report of Independent Registered Public Accounting Firm (PCAOB #596) | F-2 | |
|---|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 | |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022 | F-4 | |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2023 and 2022 | F-5 | |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 | F-6 | |
| Notes to Consolidated Financial Statements | F-7 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.